Overview
- A federal securities class action has been filed on behalf of investors who bought Altimmune shares between August 10, 2023 and June 25, 2025.
- The complaint alleges the company inflated expectations for its IMPACT Phase 2b MASH trial and concealed higher placebo responses that undercut the topline analysis.
- Altimmune’s June 26, 2025 release reported that the fibrosis reduction primary endpoint did not achieve statistical significance.
- Following the disclosure, the stock fell from $7.71 on June 25 to $3.61 on June 26, a 53.2% one-day drop.
- Rosen Law Firm, Levi & Korsinsky, and Faruqi & Faruqi are recruiting class members ahead of the October 6, 2025 lead-plaintiff deadline, and no class has been certified.